Get all premium features to the best stock analysis tool

First Ever Real-World Evidence of Eversense 365 Presented at ATTD Demonstrates Sustained Performance and Positive Impact Throughout One-Year of Wear

New data shows positive real-world impact of the world's first and only one-year CGM, with a full year of strong patient adherence, glucometrics and hypoglycemic outcomes

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration, with twiist in the US GERMANTOWN, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced fourth quarter 2025 financial results and provided a business update.

Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365

The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes

Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365

The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes